-
31.
公开(公告)号:US20230084249A1
公开(公告)日:2023-03-16
申请号:US17506324
申请日:2021-10-20
发明人: Michael Berlin , Andrew P. Crew , Hanqing Dong , Keith R. Hornberger , Lawrence B. Snyder , Jing Wang , Kurt Zimmermann
摘要: Bifunctional compounds, which find utility as modulators of androgen receptor (AR), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds AR, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
公开(公告)号:US11584743B2
公开(公告)日:2023-02-21
申请号:US17082839
申请日:2020-10-28
发明人: Andrew P. Crew , Yimin Qian , Hanging Dong , Jing Wang
IPC分类号: C07D417/14 , C07K5/062 , C07D403/12 , C07D403/14 , C07D413/14
摘要: The present disclosure relates to compounds and a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing the compounds, and processes for their preparation. The disclosure also relates to the use of the compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.
-
公开(公告)号:US20220402907A1
公开(公告)日:2022-12-22
申请号:US17360699
申请日:2021-06-28
发明人: Andrew P. Crew , Keith R. Hornberger , Jing Wang , Hanqing Dong
IPC分类号: C07D417/14 , A61P35/00 , C07D401/14 , C07D413/14 , C07D471/04
摘要: The present disclosure relates to bifunctional compounds, which find utility as modulators of Kirsten rat sarcoma protein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
34.
公开(公告)号:US20220388984A1
公开(公告)日:2022-12-08
申请号:US17359424
申请日:2021-06-25
发明人: Andrew P. Crew , Hanqing Dong , Keith R. Hornberger , Yimin Quian , Jing Wang
IPC分类号: C07D401/14 , A61K47/54 , A61P15/00 , A61P35/00 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/519 , A61K31/5386 , A61K31/551 , A61K38/05 , A61K38/06 , A61K45/06 , C07D401/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D498/10 , C07K5/078 , C07K5/083
摘要: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
35.
公开(公告)号:US20220378726A1
公开(公告)日:2022-12-01
申请号:US17354941
申请日:2021-06-22
发明人: Andrew P. Crew , Lawrence B. Snyder , Jing Wang , Hanqing Dong , Yimin Qian , Michael Berlin
IPC分类号: A61K31/166 , A61K31/405 , A61K47/54 , A61P35/00 , A61K38/45 , C12N9/10 , A61K31/351 , C07D471/04 , C07D401/14 , C07D405/14 , C07D405/12 , C07D417/14 , C07D409/14 , A61K47/55
摘要: The present disclosure relates to bifunctional compounds, which find utility as modulators of enhancer of zeste homolog 2 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
公开(公告)号:US20220331297A1
公开(公告)日:2022-10-20
申请号:US17196695
申请日:2021-03-09
发明人: Andrew P. Crew , Erika Araujo
IPC分类号: A61K31/437 , A61P25/00 , C07D487/04 , C07D417/14 , A61P29/00 , C07D401/14 , A61K47/64 , A61P21/04 , A61P37/06 , A61P35/00 , A61K31/422 , A61K31/427 , A61K31/551 , A61K38/20 , A61K38/53
摘要: The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
公开(公告)号:US11065231B2
公开(公告)日:2021-07-20
申请号:US16194094
申请日:2018-11-16
发明人: Andrew P. Crew , Erika Araujo
IPC分类号: A61K31/437 , A61P25/00 , C07D487/04 , C07D417/14 , A61P29/00 , C07D401/14 , A61K47/64 , A61P21/04 , A61P37/06 , A61P35/00 , A61K31/422 , A61K31/427 , A61K31/551 , A61K38/20 , A61K38/53
摘要: The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
公开(公告)号:US20210171470A1
公开(公告)日:2021-06-10
申请号:US16888484
申请日:2020-05-29
发明人: Andrew P. Crew , Keith R. Hornberger , Lawrence B. Snyder , Kurt Zimmermann , Jing Wang , Michael Berlin , Craig M. Crews , Hanqing Dong
IPC分类号: C07D233/42 , A61K31/166 , C07D211/76 , C07D241/04 , C07D231/12 , C07D213/72 , C07D205/04 , C07D237/08 , C07D239/24 , C07D221/20 , A61K31/277 , A61K47/10 , A61K31/02 , A61K31/497 , C07D209/48 , C07D401/14 , A61K45/06
摘要: The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.
-
公开(公告)号:US20210040044A1
公开(公告)日:2021-02-11
申请号:US17006193
申请日:2020-08-28
发明人: Andrew P. Crew , Keith R. Hornberger , Lawrence B. Snyder , Kurt Zimmermann , Jing Wang , Michael Berlin , Hanqing Dong
IPC分类号: C07D233/42 , C07D221/20 , C07D211/76 , C07D205/04 , C07D239/24 , A61K45/06 , C07D209/48 , C07D237/08 , C07D213/72 , A61K31/02 , C07D401/14 , A61K31/166 , A61K31/277 , C07D231/12 , C07D241/04 , A61K31/497 , A61K47/10
摘要: The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.
-
40.
公开(公告)号:US10899742B1
公开(公告)日:2021-01-26
申请号:US16744414
申请日:2020-01-16
发明人: Andrew P. Crew , Yimin Qian , Hanqing Dong , Jing Wang
IPC分类号: A61K31/496 , C07D401/14 , A61K47/54 , A61P15/00 , A61P35/00 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/519 , A61K31/5386 , A61K31/551 , A61K38/05 , A61K38/06 , A61K45/06 , C07D401/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D498/10 , C07K5/078 , C07K5/083 , C07K5/062
摘要: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, inhibitors of apoptosis proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
-
-
-
-
-
-
-
-